Viracta Therapeutics, Inc. (Nasdaq: VIRX) has announced that its pivotal NAVAL-1 clinical trial has achieved the efficacy threshold for expansion in relapsed or refractory EBV-positive peripheral T-cell lymphoma (R/R EBV+ PTCL). This milestone allows the trial to move into Stage 2, indicating a strong signal of efficacy in treating this type of cancer.
The NAVAL-1 trial is a global, multicenter study evaluating the effectiveness of Nana-val, an all-oral combination therapy consisting of nanatinostat and valganciclovir, in patients with R/R EBV+ lymphoma. The trial employs a two-stage design, with additional patients being enrolled in Stage 2 if a pre-specified activity threshold is reached within a specific lymphoma subtype.
Mark Rothera, President and CEO of Viracta, expressed optimism about the results: "Given the lack of effective therapies available for patients with PTCL, today's announcement represents an important step towards addressing a pressing unmet medical need."
Keywords: 1. Viract